NTC, BACKED BY WISE EQUITY, COMPLETES THE ACQUISITION OF PHARMATHEN'S OPHTHALMOLOGY BUSINESS

Supported by Wise Equity, NTC expands its portfolio in the glaucoma segment strengthening its competitive position in the European eye care market.

This transaction allows NTC to reach about €100 million of revenues, of which more than 80% in ophthalmology, and to further expand its international presence by also including the U.S. market.